Kiniksa Pharmaceuticals
KNSA
125 hedge funds and large institutions have $444M invested in Kiniksa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 8 closing their positions.
275% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 8
156% more call options, than puts
Call options by funds: $6.89M | Put options by funds: $2.69M
20% more funds holding
Funds holding: 104 → 125 (+21)
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
16% more capital invested
Capital invested by funds: $383M → $444M (+$61M)
0.51% more ownership
Funds ownership: 86.8% → 87.31% (+0.51%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.8M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.47M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$3.55M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$2.91M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$26.3M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$8.74M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$4.31M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.07M |
| 5 |
Walleye Capital
New York
|
-$2.55M |
KNSA Hedge Fund Activity: Q4 2022 in Review
125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2022, worth a combined $444M — up 16% from $383M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KNSA positions and 8 closed out — a net gain of 22 holders — while 41 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $12.8M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $26.3M.
- 125 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2022, up from 104 in Q3 2022.
- Funds reported $444M of Kiniksa Pharmaceuticals stock for Q4 2022, up 16% quarter-over-quarter.
- 30 funds opened new Kiniksa Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +22 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2022 was State Street, an estimated $12.8M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $26.3M sold.
Based on aggregated 13F filings for Q4 2022.